The U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) plans to help bring a vaccine for the Zika virus to market immediately via Emergent BioSolutions Inc., which also developed the anthrax vaccine.
Over the past several months, we have received information from news reports, local and state departments of health, and from the Centers for Disease Control and Prevention (CDC) about the Zika virus, a mosquito-transmitted disease, and the devastating outcomes experienced by some pregnant women who contracted the Zika virus during pregnancy.
With summer here and concern growing about the spread of the Zika virus to the United States, pediatricians might notice more patients inquiring about how to safely repel mosquitoes and their disease-inducing bites.
We are excited to reveal a new avenue of clinically relevant information and education. Through a partnership with Dermatology Times magazine, we will bring you relevant content culled from the pages of each monthly issue. This month, we've packaged content related to the Zika virus along with insights in managing your pediatric patients.
For Contemporary OB/GYN, Dr Bobby Lazzara explains key findings from a special report published in The New England Journal of Medicine. The report looked at the teratogenic element of the Zika virus and whether causality exists.
With summer around the corner and increasing concern about the spread of the Zika virus in the United States, dermatologists might notice more patients inquiring about how to safely repel mosquitos and their disease-inducing bites.